摘要
利奈唑胺(linezolid,LZD)对耐甲氧西林金黄色葡萄球菌、青霉素耐药肺炎球菌和耐万古霉素肠球菌具有良好活性,但血小板毒性大大限制其应用。近年来,利奈唑胺诱导血小板减少症(linezolid-induced thrombocytopenia,LIT)相关研究取得较大进展。LZD被发现与骨髓抑制、抑制巨核细胞释放、氧化应激及免疫破坏等机制密切相关。此外,大量临床研究也总结出LIT的风险因素,并探索出LZD的剂量调整方法,成为LIT防治的突破口。然而不同文献中LIT发病机制、风险因素和LZD剂量调整的差异较大,本文对此开展综述,以期为临床防治LIT提供思路。
Linezolid( LZD) has good antibacterial activity against methicillin-resistant staphylococcus aureus,penicillin-resistant pneumococcus and vancomycin-resistant enterococci. However,platelet toxicity greatly limits its clinical application. In recent years,significant progress has been acheived in studies of the pathogenesis and clinical risk factors of linezolid-induced thrombocytopenia( LIT). LZD has been found to be closely related to bone marrow suppression, inhibition of platelet release,oxidative stress and immune destruction to result in low platelet count. In addition,a large number of clinical studies had also summarized the risk factors of LIT,and explored the dose adjustment methods of LZD,which became the breakthrough of prevention and treatment for LIT. However,there are many different kinds of opinoins in these literatures. This article reviews the pathogenesis,risk factors,and dose adjustment of LIT,with a view to providing ideas for clinical prevention and treatment of LIT.
作者
钟玲
邵华
陈燕
胡琳璘
于锋
ZHONG Ling;SHAO Hua;CHEN Yan;HU Linlin;YU Feng(School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing 210009,Jiangsu,China;Department of Pharmacy,Zhongda Hospital,Southeast university,Nanjing 210009,Jiangsu,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2018年第10期1196-1200,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
国家自然科学基金资助项目(81503340)
江苏省自然科学基金资助项目(BK20150645)
